This trial is evaluating whether GSK3901961 will improve 4 primary outcomes and 14 secondary outcomes in patients with Cancer. Measurement will happen over the course of Until disease progression (up to 4 years).
This trial requires 50 total participants across 7 different treatment groups
This trial involves 7 different treatments. GSK3901961 is the primary treatment being studied. Participants will be divided into 7 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
What are the specific causes of cancer? The most important factors include genetic predisposition, environmental exposures such as ionizing radiation from radiation therapy, viral, bacterial or parasitic infection, and cigarette smoking. Tobacco smoking is the number one cause of cancer worldwide, responsible for approximately 36% of deaths in developed countries and 50-60% of cancer cases in developing countries. In 2012 about 16.7 million cancer deaths (about 3.8 million cancer related deaths) were reported to the World Health Organization. This means about one person dies of cancer every minute, and about 870,000 people in the United States will have cancer the year they die, making cancer the most frequent cause of death. There are many types of cancer.
An estimated 2 million cases of cancer are diagnosed each year. The majority (70%) are non-melanoma skin cancers. Nearly half (42%) of all cancer diagnoses, and one-third of all cancer deaths are attributed to cigarette smoking, the second most common single modifiable risk factor after diet and alcohol. In the US in 2006 (the most recent year for which data are available), the age-adjusted rate per 100,000 population of cancer is as follows: lung cancer, 2.1; colon cancer, 8.4; prostate cancer, 12.4; breast cancer, 16.6; and other cancers, 26.7.
Sometimes the symptoms are so strong that they interfere with daily activities. For instance, unexplained weight loss can be an early warning sign for cancer. Other signs include itchiness (scabies), night sweats, swollen lymph nodes, swelling in the neck (gland cancer), bleeding into a wound or nose (cancer of the esophagus or nasopharynx) and a red swelling behind the ear (cancer of the thyroid or cancer of the parathyroid gland).
Cancer is a complex disease that has many possible causes. In America, cancer is now the leading cause of death in young adults and children and the number of new cases of cancer is increasing. People must be aware that early detection, treatment, and recovery can prevent many of the complications of cancer.
There is no known cure for cancer. Treatment can produce some degree of remission, long-term symptom control and stabilization. A small number of patients with metastatic cancer may have a prolonged response to palliative treatment.
Chemotherapy therapy, hormonal therapy, radiotherapy, and targeted therapy are common cancer therapies.\n\nThere is still no cure available and treatment is typically aimed at slowing symptoms and improving quality of life.\n\n- Cancers and the environment\n- Medical tourism\n- Cancer and the aging community"
"Neoscleroporthe\n\nNeoscleroporthe is a genus of fungi in the Meliolaceae family; according to the 2007 Outline of Ascomycota, the placement in this family is uncertain.
GSK3901961 has shown promise as a new therapeutic agent of osteosarcoma (OP) in a recent phase I study in patients with advanced, previously treated OP. The therapeutic role of GSK390260 in this subset was assessed in phase II clinical trial for OP, in combination with the glucosamine glucosamine sulfate (GSN) and high-dose ascorbic acid (vitamin C) (DAVA). The safety, pharmacology, and tolerability of GSK390260 in OS are being explored. A Phase III GSK390260 study for OS was completed in December 2016. It is expected that results will be available in late 2019 or early 2020.
A multitude of biological factors exist, but no single mechanism. Rather, multiple factors act together in conjunction. The primary factor in cancer is uncontrolled proliferation. Cancer cells are able to replicate in a fast and massive manner, which is caused by increased proliferation pathways. This includes a high metabolism rate and the ability to survive in harsh environments. When the cells divide rapidly, the result is a large tumor.
Clinical trials can help people with cancer to make well-informed medical decisions. Although a medical team can do this part of the trial, patients can benefit from talking freely with an oncologist about treatment options of their disease, regardless of the status of trials.
The anti-cancer efficacy of gsk3901961 was demonstrated in preclinical models of breast cancer/leukemia. Results from a recent paper identify a therapeutic strategy for combinatorial cancer therapy that involves the inhibition of the PI3K/AKT/mTOR pathway and warrants clinical evaluation.
Clinical trials of gsk3901961 for the treatment of adult patients with relapsed or refractory B-cell lymphoma have been terminated. This is because of unacceptably high toxicity in a subset of patients who were treated with the agent. Clinical trials using gsk3901961 in patients with metastatic renal cell carcinoma are ongoing. The safety profile of gsk3901961 in the treatment of these patients remains to be determined.
Doses of gsk3901961 given within the context of this trial of three weekly doses ranged from 400 mg to 800 mg, in doses of 4 to 16 mg/kg. Subjects who were receiving combination therapy with docetaxel had a dose requirement of 8 mg/kg every two weeks instead of the 6 mg/kg dose required by those receiving the drug as monotherapy.